Wells Fargo & Company Bio Xcel Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
68Shares Held
6.99MCall Options Held
101KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA1.2MShares$744,8530.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$273,2240.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$184,7860.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA173KShares$107,4570.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$80,5180.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $17.4M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...